XOMA ROYALTY CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.97 USD | -0.11% |
|
+9.41% | +45.78% |
| 10/07 | XOMA Corporation will Change its Name to XOMA Royalty Corporation | CI |
| 09/07 | Xoma Changes Name to Xoma Royalty | MT |
| Sales 2024 * | 21M 1.75B | Sales 2025 * | 26.93M 2.25B | Capitalization | 314M 26.23B |
|---|---|---|---|---|---|
| Net income 2024 * | -22M -1.84B | Net income 2025 * | -15M -1.25B | EV / Sales 2024 * | 14.9 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.7 x |
| P/E ratio 2024 * |
-14.2
x | P/E ratio 2025 * |
-20.5
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.47% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.11% | ||
| 1 week | +9.41% | ||
| Current month | +13.85% | ||
| 1 month | +6.69% | ||
| 3 months | +10.81% | ||
| 6 months | +33.78% | ||
| Current year | +45.78% |
1 week
24.65
27.05
1 month
21.2727.10
Current year
18.5727.36
1 year
13.4827.36
3 years
13.4837.50
5 years
13.4846.32
10 years
3.96119.00
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 01/23/01 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 14/06/14 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 03/23/03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 06/21/06 |
| Chairman | 68 | 26/10/26 | |
Joseph Limber
BRD | Director/Board Member | 71 | 12/12/12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 26 M€ | -1.62% | - | |
| 0.00% | 32 M€ | +6.24% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/24/15 | 26.97 | -0.11% | 26,063 |
| 12/24/12 | 27 | +3.13% | 14,540 |
| 11/24/11 | 26.18 | +1.95% | 26,692 |
| 10/24/10 | 25.68 | +4.56% | 12,859 |
| 09/24/09 | 24.56 | -0.37% | 12,382 |
Delayed Quote Nasdaq, July 16, 2024 at 01:30 am IST
More quotes
XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
06/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
26.97
USD
Average target price
58
USD
Spread / Average Target
+115.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +45.78% | 314M | |
| +20.63% | 127B | |
| +24.16% | 27.67B | |
| -20.17% | 20.33B | |
| -16.06% | 16.79B | |
| -18.07% | 15.63B | |
| -47.70% | 14.65B | |
| +11.92% | 14.84B | |
| +58.32% | 14.43B | |
| +149.98% | 12.49B |
- Stock Market
- Equities
- XOMA Stock
